WASHINGTON, March 4- War rooms of lawmakers and their aides in the U.S. Congress are working furiously to try to influence the Supreme Court's nine justices who will hear arguments on Wednesday on the future of President Barack Obama's landmark healthcare law. Senator John Barrasso of Wyoming, a member of the Republican leadership, is spearheading his party's...» Read More
A preview of the U.S. markets ahead of the open, with CNBC's Kelly Evans, including a look at a possible verdict today from the Supreme Court on President Obama's health care law.
The White House is preparing contingency plans if the Supreme Court declares part of President Obama's signature health care reform unconstitutional, The New York Times reports.
How the “Mad Money” host recommends investors position themselves regardless of how the high court rules on health care reform.
Mad Money host Jim Cramer looks ahead to next week's major economic data, and suspects the markets would see a sharp sell-off if the Supreme Court rules in favor of Obamacare.
At this very moment, the economic basis of the entire health-care system is up in the air, as a result of the imminent U.S. Supreme Court opinion in the health care reform law cases. Court observers expect the decision any day now, and most likely before the end of June.
"More importantly, Europe and the emerging markets are worse," says Jack Welch, former GE chairman & CEO, sharing his thoughts on the state of the global economy, and the impact of regulations on economic recovery.
One of the biggest misconceptions about President Obama's health care overhaul isn't who the law will cover, but rather who it won't. If it survives Supreme Court scrutiny, an estimated 26 million Americans will remain without coverage.
Should the U.S. Supreme Court strike down health care reform, here’s how Cramer recommends playing it.
Toby Cosgrove, Cleveland Clinic CEO & president, discusses the state of the U.S. health care system and weighs in on the future of President Obama's health reform law.
Dr. Gary Gottlieb, Partners HealthCare president and CEO, discusses why he is giving President Obama's Health Care Reform law good grades, ahead of a pending Supreme Court decision on the legislation.
A look at the winner and losing stock trades, if the Supreme Court overturns President Obama's health insurance reform law, with Gary Brode, Silver Arrow Investment Management.
If the Supreme Court shoots down Obamacare, what does that mean for big pharma? Deutsche Bank analyst Barbara Ryan weighs in.
Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.
Every industry has down cycles, but for several companies in the videogame space, 2012 can't end soon enough.
The Supreme Court says home loan applicants cannot sue a mortgage company for charging them a loan discount fee without giving them a loan discount.
Twenty-two states have joined Montana in fighting to prevent the Supreme Court's Citizens United decision from being used to strike down state laws restricting corporate campaign spending.
Someone is looking for a big move in Cigna. The health insurer’s last earnings report missed estimates, but the company did raise full-year guidance. An even bigger catalyst is expected in June, when the U.S. Supreme Court will rule on the constitutionality of national health care.
The Supreme Court, suddenly at the heart of presidential politics, is preparing what could be blockbuster rulings on health care and immigration shortly before the fall election.
Cold and flu season may be over, but the healthcare sector's earnings season is just beginning. Sam Isaly, OrbiMed founder, offers insight into which stocks you should buy, sell or hold. The FMHR traders also take a look at today's biggest market movers.
After being rejected by the high court, Jeffery Skilling and his attorney will go back to the original court where he was convicted to file a defense motion for a new trial based on new evidence.